NDA 205879 · Janssen Pharms
Invokamet Xr
Canagliflozin, Metformin Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Sep 20, 2016
Approved uses
6
Original approval plus efficacy supplements
Registered trials
156
25 Phase 3, 13 recruiting
FAERS reports
134
46 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...
What it is approved for
From the label in effect Aug 24, 2026.
INVOKAMET INVOKAMET is a combination of canagliflozin and metformin HCl immediate-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. INVOKAMET XR INVOKAMET XR is a combination of canagliflozin and metformin HCl extended-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). End-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. Limitations of Use INVOKAMET or INVOKAMET XR are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse...
Mechanism: Canagliflozin SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT G ), and thereby increases urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium reabsorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2024 Supplement 23 · Efficacy · priority review Medication GuideLabelLetter
- Aug 18, 2020 Supplement 17 · Efficacy LetterLabel
- Jan 27, 2020 Supplement 11 · Efficacy LetterLabel
- Oct 29, 2018 Supplement 7 · Efficacy LabelLetter
- Jan 2, 2018 Supplement 2 · Efficacy LabelLetter
- Sep 20, 2016 Original approval · Type 4 - New Combination LetterLabelReview
4 products under this application
- INVOKAMET XR · CANAGLIFLOZIN 150MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVOKAMET XR · CANAGLIFLOZIN 50MG; METFORMIN HYDROCHLORIDE 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVOKAMET XR · CANAGLIFLOZIN 150MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
- INVOKAMET XR · CANAGLIFLOZIN 50MG; METFORMIN HYDROCHLORIDE 1GM · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Canagliflozin" as an intervention, any sponsor and status, largest first.
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01989754 · 5,813 participants · Start Jan 16, 2014 · Primary completion Feb 23, 2017
Drug: Placebo; Canagliflozin, 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Albuminuria
Sites: Little Rock, Arkansas; Carmichael, California; Concord, California · 341 sites in all
- Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02065791 · 4,401 participants · Start Feb 17, 2014 · Primary completion Oct 30, 2018
Drug: Canagliflozin; Placebo · For: Diabetes Mellitus, Type 2; Diabetic Nephropathy
Sites: Birmingham, Alabama; Montgomery, Alabama; Tempe, Arizona · 575 sites in all
- CANVAS - CANagliflozin cardioVascular Assessment StudyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01032629 · 4,330 participants · Start Dec 9, 2009 · Primary completion Feb 22, 2017
Drug: Placebo; Canagliflozin (JNJ-28431754) 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Sites: Birmingham, Alabama; Mesa, Arizona; Tucson, Arizona · 305 sites in all
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTEPivotal-lookingCompleted
Matthew Neal MDAcademic, hospital or other
NCT04505774 · 3,591 participants · Start Sep 4, 2020 · Primary completion Aug 31, 2023
Drug: theraputic heparin; prophylactic heparin and 3 more · For: Covid19
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 101 sites in all
- CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepiridePivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00968812 · 1,452 participants · Start Sep 2009 · Primary completion Dec 2011
Drug: Glimepiride; Canagliflozin (JNJ-28431754) and 1 more · For: Diabetes Mellitus, Type 2
Sites: Calera, Alabama; Gilbert, Arizona; Mesa, Arizona · 138 sites in all
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01387737 · 1,299 participants · Start May 2011 · Primary completion Nov 2012
Drug: TA-7284-Low; TA-7284-High · For: Type 2 Diabetes Mellitus
Sites: Chugoku, Japan; Hokkaido, Japan; Kanto, Japan · 7 sites in all
- The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01106677 · 1,284 participants · Start May 2010 · Primary completion Oct 2011
Drug: Placebo; Canagliflozin and 2 more · For: Diabetes Mellitus, Type 2
Sites: Little Rock, Arkansas; Fountain Valley, California; National City, California · 125 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea11
- blood glucose increased9
- off label use9
- weight decreased8
- drug dose omission7
- inappropriate schedule of drug administration6
- product dose omission6
- vomiting6
- asthenia5
- dizziness5
- drug ineffective5
- dyspnoea5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 5 |
| 2017 | 34 |
| 2018 | 28 |
| 2019 | 16 |
| 2020 | 21 |
| 2021 | 8 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Invokamet XR (Canagliflozin/Metformin HCl)
2024 spending
$10.2M
Beneficiaries
2,419
10,648 claims
Per beneficiary
$4,197
$9.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $22,087,871 |
| 2021 | $16,528,368 |
| 2022 | $16,196,326 |
| 2023 | $13,108,387 |
| 2024 | $10,151,739 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F, Webb DR, Htike ZZ, et al. · Diabetes Obes Metab 2016 · Systematic Review, Network Meta-Analysis
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Neal B, Perkovic V, Mahaffey KW, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, et al. · Pharmacol Res 2021 · Systematic Review
- Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX, Liu LY, Zhang CX, et al. · Front Endocrinol (Lausanne) 2023 · Comparative Study, Research Support, Non-U.S. Gov't
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.